Search results for Oleclumab

Oleclumab Biosimilar – Anti-NT5E, CD73 mAb – Research Grade, ProteoGenix, PX-TA1471

Description of Oleclumab Biosimilar – Anti-NT5E, CD73 mAb – Research Grade Introduction Oleclumab Biosimilar, also known as Anti-NT5E or CD73 monoclonal antibody, is a research grade antibody that has been developed for its potential therapeutic applications. This antibody targets the CD73 protein, which is a key enzyme involved in the production of adenosine, a molecule that plays a crucial role in regulating the immune response. In this article, we will discuss the structure, activity, and potential applications of Oleclumab Biosimilar. Structure of Oleclumab Biosimilar Oleclumab Biosimilar is a monoclonal antibody, which means it is a type of protein made in the laboratory that can bind specifically to a particular target molecule. The antibody is made up of two heavy chains and two light chains, each with a specific amino acid sequence. The heavy and light chains are connected by disulfide bonds, forming a Y-shaped structure. The variable regions of the antibody, also known as the antigen-binding sites, are located at the tips of the Y-shaped structure. These regions are responsible for binding to the specific target molecule, CD73, with high affinity and specificity. The constant regions of the antibody, on the other hand, are responsible for the effector functions of the antibody, such as activating the immune system. Activity of Oleclumab Biosimilar Oleclumab Biosimilar specifically targets the CD73 protein, which is found on the surface of various immune cells, including T cells, B cells, and natural killer cells. CD73 is an ecto-5′-nucleotidase enzyme that converts extracellular ATP to adenosine. Adenosine is a potent immunosuppressive molecule that can inhibit the activity of immune cells and promote tumor growth. By binding to CD73, Oleclumab Biosimilar blocks its activity, preventing the conversion of ATP to adenosine. This leads to an increase in extracellular ATP levels, which can activate immune cells and enhance their anti-tumor activity. Additionally, the antibody can also directly induce cell death in cancer cells that express CD73, further contributing to its anti-tumor effects. Applications of Oleclumab Biosimilar The potential therapeutic applications of Oleclumab Biosimilar are mainly focused on its anti-tumor effects. As mentioned earlier, the antibody can enhance the activity of immune cells and directly induce cell death in cancer cells, making it a promising candidate for cancer immunotherapy. Several preclinical studies have shown the efficacy of Oleclumab Biosimilar in various types of cancer, including breast, lung, and colon cancer. In a study on breast cancer, treatment with Oleclumab Biosimilar led to a significant reduction in tumor growth and improved survival in mice. Similarly, in a study on lung cancer, the antibody was found to enhance the activity of immune cells and inhibit tumor growth. Apart from its potential as a cancer treatment, Oleclumab Biosimilar may also have applications in other diseases. CD73 has been implicated in various inflammatory and autoimmune disorders, and targeting it with Oleclumab Biosimilar may have therapeutic benefits in these conditions. Conclusion Oleclumab Biosimilar, also known as Anti-NT5E or CD73 monoclonal antibody, is a research grade antibody that specifically targets the CD73 protein. By blocking the activity of CD73, the antibody can enhance the anti-tumor activity of immune cells and directly induce cell death in cancer cells. It has shown promising results in preclinical studies and may have potential applications in cancer immunotherapy and other diseases. Further research and clinical trials are needed to fully understand the potential of Oleclumab Biosimilar as a therapeutic agent.

Oleclumab, Kyinno, KB-1317

Oleclumab, Abbexa, abx831429

Oleclumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting NT5E/CD37, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Oleclumab ELISA Kit, ProteoGenix, KPTX207

Description of Oleclumab ELISA Kit Introduction Oleclumab ELISA Kit is a powerful tool used in the field of immunology for the detection and quantification of Oleclumab, a monoclonal antibody that specifically targets the programmed death ligand 1 (PD-L1) protein. This kit is widely used in research and clinical settings to study the structure, activity, and application of Oleclumab in various disease states. In this article, we will discuss the key features of the Oleclumab ELISA Kit and its importance in understanding the role of PD-L1 in immune regulation and disease progression. Structure of Oleclumab Oleclumab is a fully humanized IgG4 monoclonal antibody that binds to PD-L1 with high affinity and specificity. It is composed of two heavy chains and two light chains, each containing unique variable regions that determine its binding specificity. The variable regions of Oleclumab are derived from human B-cells, making it less immunogenic and more suitable for therapeutic use. Activity of Oleclumab The main function of Oleclumab is to block the interaction between PD-L1 and its receptor, programmed cell death protein 1 (PD-1). This interaction is a key mechanism used by cancer cells and other immune cells to evade the immune system and promote tumor growth. By inhibiting this interaction, Oleclumab enhances the anti-tumor activity of immune cells, leading to tumor regression and improved patient outcomes. The activity of Oleclumab can be measured using the Oleclumab ELISA Kit, which detects the levels of free and bound Oleclumab in biological samples. This allows researchers to monitor the pharmacokinetics of Oleclumab and assess its efficacy in clinical trials. Application of Oleclumab ELISA Kit The Oleclumab ELISA Kit has a wide range of applications in both research and clinical settings. Some of the key applications include: Drug development: The Oleclumab ELISA Kit is used to measure the levels of Oleclumab in preclinical and clinical studies, providing valuable information on its pharmacokinetics and pharmacodynamics. Biomarker discovery: PD-L1 expression is a potential biomarker for predicting response to Oleclumab therapy. The Oleclumab ELISA Kit can be used to measure PD-L1 levels in patient samples and identify potential responders to Oleclumab treatment. Disease monitoring: The Oleclumab ELISA Kit can be used to monitor PD-L1 expression in various disease states, such as cancer, autoimmune disorders, and infectious diseases. This helps in understanding the role of PD-L1 in disease progression and identifying potential therapeutic targets. Conclusion The Oleclumab ELISA Kit is a valuable tool for studying the structure, activity, and application of Oleclumab in various disease states. Its ability to accurately detect and quantify Oleclumab levels makes it an essential tool for drug development, biomarker discovery, and disease monitoring. With the growing interest in immunotherapy and the use of monoclonal antibodies, the Oleclumab ELISA Kit will continue to play a crucial role in advancing our understanding of the immune system and its role in disease.

Oleclumab ELISA Kit, Abbexa, abx395096

Oleclumab ELISA Kit is a quantitative ELISA kit for detection of Oleclumab.Oleclumab (as known as MEDI9447) is a human monoclonal antibody (mAb) being investigated for the treatment of various types of cancer like Solid Tumors, Pancreatic and Colorectal cancer. It is a monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase; NT5E) with potential antineoplastic activity. This drug was developed by MedImmune, LLC and AstraZeneca plc. In contrast with many other cancer immunotherapy agents such as checkpoint inhibitors or T cell agonists, MEDI9447 drives changes in both myeloid and lymphoid infiltrating leukocyte populations within the tumor microenvironment. Changes include significant increases in CD8 effector cells and activated macrophages, as well as a reduction in the proportions of myeloid-derived suppressor cells (MDSC) and regulatory T lymphocytes. Furthermore, these changes correlate directly with responder and non-responder subpopulations within the arms of animal studies using syngeneic tumors. Data showing additive activity between MEDI9447 and other immune-mediated therapy antibodies demonstrates the importance of relieving adenosine-mediated immunosuppression within tumors.

Oleclumab Biosimilar - Research Grade, ichor.bio, ICH5038

Detects human CD73. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Oleclumab.

Research Grade Oleclumab (HB209016), abinScience, HB209016